Clinical Trial

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN

Study acronym: ADVANCE
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A Phase III, single-arm, multicenter pediatric clinical study evaluating atrasentan in children and adolescents aged 2 to \<18 years with primary immunoglobulin A nephropathy (IgAN).
Protocol Amendment History 5 changes
notable Trial sites expanded: 6 -> 9 locations 2026-08-08
critical Recruitment opened 2026-07-15
notable Trial sites expanded: 2 -> 6 locations 2026-07-15
notable Primary completion pushed: 2030-11-29 -> 2031-09-15 2026-06-02
minor Completion pushed: 2031-01-31 -> 2032-12-13 2026-06-02
Trial Details
NCT Number NCT07498335
Lead Sponsor Novartis Pharmaceuticals
Conditions Berger Disease, Bergers Disease, IgA Nephropathy, Immunoglobulin A Nephropathy, Primary IgAN, Nephritis IgA Type, Nephropathy IgA Type
Enrollment 28 participants
Start Date 2026-08-26
Primary Completion 2031-09-15 (estimated)
Study Completion 2032-12-13 (estimated)
Updated on ClinicalTrials.gov 2026-08-07